• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Chief Financial Officer Black Jeffrey G. was granted 15,000 shares, increasing direct ownership by 5% to 289,492 units (SEC Form 4)

    2/25/25 8:59:29 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Black Jeffrey G.

    (Last) (First) (Middle)
    C/O EXAGEN INC.
    1261 LIBERTY WAY

    (Street)
    VISTA CA 92081

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    EXAGEN INC. [ XGN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Financial Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    02/21/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/21/2025 A 15,000(1) A $0 289,492 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option(right to buy) $3.58 02/21/2025 A 10,000 (2) 02/20/2035 Common Stock 10,000 $3.58 10,000 D
    Explanation of Responses:
    1. The securities awarded are in the form of restricted stock units under the issuer's 2019 Incentive Award Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock unit will vest with respect to 25% of the restricted stock units on each of the first, second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued service through the applicable vesting date. In addition, the award may become fully vested upon a qualifying termination of employment in connection with a change in control.
    2. The option is exercisable as it vests. 25% of the shares subject to the option vest on February 21, 2026, and 1/48th of the total number of shares subject to the option vest at the end of each calendar month thereafter, subject to the Reporting Person's continued service to the Issuer through each such vesting date. In addition, the stock option may become fully vested upon a qualifying termination of employment in connection with a change in control.
    Remarks:
    /s/ Jeffrey G. Black 02/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $XGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Nmsic Co-Investment Fund, L.P. sold $1,155,000 worth of shares (350,000 units at $3.30) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/27/25 4:15:57 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John was granted 8,621 shares, increasing direct ownership by 1% to 746,214 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      3/4/25 6:48:32 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Chief Financial Officer Black Jeffrey G. was granted 15,000 shares, increasing direct ownership by 5% to 289,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      2/25/25 8:59:29 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

      CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter's option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting u

      5/9/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Prices Public Offering of Common Stock

      CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satis

      5/8/25 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Proposed Public Offering of Common Stock

      CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has commenced an underwritten public offering of shares of its common stock. In connection with the offering, Exagen intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares of common stock to be sold in the offering will be sold by Exagen. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Canac

      5/7/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Financials

    Live finance-specific insights

    See more
    • Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

      CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194  $27,267 Trailing-twelve-month average selling price (ASP) $419  $377           Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million

      5/5/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

      4/21/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

      Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.   Three Months Ended December 31, Year Ended December 31,   2024   2024 (in thousands, except ASP data)  Revenue $13,655  $55,641 Gross margin  62.1%  59.5%Operating expenses $11,860  $46,748 Loss from operations $(3,383) $(13,636)Net los

      3/11/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exagen downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight

      8/5/22 9:00:50 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Keybanc reiterated coverage on Exagen with a new price target

      Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously

      11/11/21 4:33:21 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Exagen with a new price target

      Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00

      10/15/21 7:34:02 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

      CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

      8/1/24 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Changes to the Board of Directors

      CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief

      4/26/24 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Appoints Paul Kim to Board of Directors

      SAN DIEGO, July 24, 2023 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, announced today that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023. Mr. Kim currently serves as Chief Financial Officer of Fulgent Genetics (NASDAQ:FLGT), a full-service genomic testing company built around a foundational technology platform. He has held that position since February 2016 and led growth initiatives increasing revenues from $10M in 2015 to $990M in 2021, during the COVID-19 era. Mr. Kim has over 30 years working in accounting and finance, and over 15 years as a Chief Financial Officer of several public

      7/24/23 4:05:00 PM ET
      $FLGT
      $XGN
      Medical Specialities
      Health Care

    $XGN
    SEC Filings

    See more
    • SEC Form 8-K filed by Exagen Inc.

      8-K - EXAGEN INC. (0001274737) (Filer)

      5/9/25 4:05:59 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 424B5 filed by Exagen Inc.

      424B5 - EXAGEN INC. (0001274737) (Filer)

      5/8/25 4:08:47 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 8-K filed by Exagen Inc.

      8-K - EXAGEN INC. (0001274737) (Filer)

      5/8/25 4:06:09 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exagen Inc.

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      12/12/24 5:00:54 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 2:42:55 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 7:12:55 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/19/24 7:24:38 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/18/24 6:32:33 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      5/16/24 8:02:50 PM ET
      $XGN
      Medical Specialities
      Health Care